PMID- 27600402
OWN - NLM
STAT- MEDLINE
DCOM- 20170411
LR  - 20170411
IS  - 1607-8454 (Electronic)
IS  - 1024-5332 (Linking)
VI  - 22
IP  - 2
DP  - 2017 Mar
TI  - Impact of serum immunoglobulins level and IL-18 promoter gene polymorphism among 
      Egyptian patients with idiopathic thrombocytopenic purpura.
PG  - 99-104
LID - 10.1080/10245332.2016.1221213 [doi]
AB  - OBJECTIVES: Based on the concept of immune dysregulation in immune 
      thrombocytopenic purpura (ITP) and that Interleukin-18 (IL-18) is an inflammatory 
      cytokine that plays an important role in autoimmune disease by inducing 
      interferon-gamma secretion; this study aimed to assess a possible association between 
      the IL-18 promoter polymorphisms (-607 C/A site) and genetic susceptibility to 
      ITP and the impact of the immunoglobulins (Igs) concentrations level on disease 
      severity and response to therapy. METHODS: A cross-section study was done on 105 
      patients' age range from 10 to 28 years, with newly diagnosed ITP at the Oncology 
      Center Mansoura University over the past 2 years and 100 healthy subjects as a 
      control group. For all patients and controls, the IL-18 promoter polymorphism 
      (-607 C/A site) as well as serum Ig (IgG, IgM, IgA) concentration was determined. 
      RESULTS: The IL-18 promoter polymorphism (-607 C/A site) was not significantly 
      different between ITP patients and normal controls. The number of patients 
      respond to standard line of therapy was significantly higher in those with low 
      IgA levels as compared to those with high IgA levels (P = 0.02). On the other 
      hand, the number of patients respond to standard therapy was significantly higher 
      in those patients with high IgM levels as compared to those with low IgM levels 
      (54.7 vs. 36.5%) (P < 0.05). The number of patients with bleeding manifestation 
      was significantly higher among those with high IgA as compared to those with low 
      IgA (43 of 79, 54.4%; vs. 36 of 79, 45.6%; P = 0.04). A change in IgG levels was 
      not associated with response to treatment, bleeding tendency, or platelet counts. 
      CONCLUSION: There is no association between IL-18 promoter polymorphisms (-607 
      C/A site) and genetic susceptibility to ITP. High IgA and low IgM levels are a 
      bad index for treatment response to standard therapy.
FAU - Aref, Salah
AU  - Aref S
AD  - a Hematology Unit, Clinical Pathology Department, Mansoura Oncology Center , 
      Mansoura Faculty of Medicine , Egypt.
FAU - El-Ghonemy, Mohamed Sabry
AU  - El-Ghonemy MS
AD  - a Hematology Unit, Clinical Pathology Department, Mansoura Oncology Center , 
      Mansoura Faculty of Medicine , Egypt.
FAU - El-Aziz, Sherin Abd
AU  - El-Aziz SA
AD  - a Hematology Unit, Clinical Pathology Department, Mansoura Oncology Center , 
      Mansoura Faculty of Medicine , Egypt.
FAU - Abouzeid, Tarek
AU  - Abouzeid T
AD  - b Clinical Hematology Unit, Mansoura Oncology Center , Mansoura Faculty of 
      Medicine , Egypt.
FAU - Talaab, Mona
AU  - Talaab M
AD  - b Clinical Hematology Unit, Mansoura Oncology Center , Mansoura Faculty of 
      Medicine , Egypt.
FAU - El-Sabbagh, Amr
AU  - El-Sabbagh A
AD  - c Medical Microbiology and Immunology , Mansoura Faculty of Medicine , Egypt.
LA  - eng
PT  - Journal Article
DEP - 20160906
PL  - England
TA  - Hematology
JT  - Hematology (Amsterdam, Netherlands)
JID - 9708388
RN  - 0 (Immunoglobulins)
RN  - 0 (Interleukin-18)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Cross-Sectional Studies
MH  - Egypt
MH  - Female
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Immunoglobulins/*blood
MH  - Interleukin-18/*genetics
MH  - Male
MH  - Polymorphism, Genetic
MH  - Purpura, Thrombocytopenic, Idiopathic/*blood/*genetics
MH  - Young Adult
OTO - NOTNLM
OT  - IL-18
OT  - ITP
OT  - immunoglobulin
EDAT- 2016/09/08 06:00
MHDA- 2017/04/12 06:00
CRDT- 2016/09/08 06:00
PHST- 2016/09/08 06:00 [pubmed]
PHST- 2017/04/12 06:00 [medline]
PHST- 2016/09/08 06:00 [entrez]
AID - 10.1080/10245332.2016.1221213 [doi]
PST - ppublish
SO  - Hematology. 2017 Mar;22(2):99-104. doi: 10.1080/10245332.2016.1221213. Epub 2016 
      Sep 6.